Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Moodys
US Army
Argus Health
UBS
Johnson and Johnson
Julphar
Queensland Health
Dow

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,841,330

« Back to Dashboard

Summary for Patent: 8,841,330
Title:Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s): Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Orange, CT), Khire; Uday (Hamden, CT), Lowinger; Timothy B. (Nishinomiya, JP), Scott; William J. (Guilford, CT), Smith; Roger A. (Madison, CT), Wood; Jill E. (North Haven, CT)
Assignee: Bayer Healthcare LLC (Whippany, NJ)
Application Number:13/368,812
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,841,330
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,841,330

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,841,330

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,897,623 .omega.-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors ➤ Try a Free Trial
7,351,834 .omega.-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors ➤ Try a Free Trial
8,124,630 .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors ➤ Try a Free Trial
7,928,239 Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,841,330

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 73731 ➤ Try a Free Trial
Taiwan I269791 ➤ Try a Free Trial
Turkey 200102020 ➤ Try a Free Trial
Tunisia SN00010 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Citi
Johnson and Johnson
Merck
Teva
Julphar
Covington
Colorcon
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.